Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Blood Protein Electrophoresis
/ methods
Cyclophosphamide
Doxorubicin
Female
Follow-Up Studies
Humans
Lymphoma, Follicular
/ drug therapy
Male
Middle Aged
Monoclonal Gammopathy of Undetermined Significance
/ blood
Neoplasm Grading
/ methods
Prednisone
Prognosis
Progression-Free Survival
Rituximab
Tumor Microenvironment
Vincristine
Watchful Waiting
beta 2-Microglobulin
/ blood
follicular lymphoma
prognosis
serum immunofixation electrophoresis
serum monoclonal component
survival
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
03
08
2020
accepted:
09
09
2020
pubmed:
18
11
2020
medline:
25
9
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
The presence of a serum monoclonal component has been associated with poor outcomes in some lymphomas. However, data in follicular lymphoma (FL) are scarce. We studied 311 FL patients diagnosed at a single institution, for whom information on serum immunofixation electrophoresis (sIFE) at diagnosis was available. Baseline characteristics and outcomes were compared between patients with a positive (+sIFE) and a negative sIFE (-sIFE). sIFE was positive in 82 patients (26%). Baseline features were comparable between both groups, except for an older age and higher proportion of elevated β
Substances chimiques
R-CHOP protocol
0
beta 2-Microglobulin
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-306Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. France: Lyon; 2017.
Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37: 2815-24.
Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516-22.
Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426-33.
Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178:699-708.
Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5:e359-e367.
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555-62.
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111-22.
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-65.
Azar HA, Hill WT, Osserman EF. Malignant lymphoma and lymphatic leukemia associated with myeloma-type serum proteins. Am J Med. 1957;23:239-49.
Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134:2022-35.
Alexanian R. Monoclonal gammopathy in lymphoma. Arch Intern Med. 1975;135:62-6.
Economopoulos T, Papageorgiou S, Pappa V, Papageorgiou E, Valsami S, Kalantzis D, et al. Monoclonal gammopathies in B-cell non-Hodgkin’s lymphomas. Leuk Res. 2003;27:505-8.
Cox MC, Di Napoli A, Scarpino S, Salerno G, Tatarelli C, Talerico C, et al. Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. PLoS One. 2014;9:e93903.
Zhang Y, Wei Z, Li J, Gao R, Liu P. Monoclonal gammopathies regardless of subtypes are associated with poor prognosis of diffuse large B-cell lymphoma A STROBE-compliant article. Medicine. 2018;97:e11719.
Li Y, Wang L, Zhu HY, Liang JH, Wu W, Wu JZ, et al. Prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma. Br J Haematol. 2018;182:131-4.
Papageorgiou SG, Thomopoulos TP, Spathis A, Bouchla A, Glezou I, Stavroulaki G, et al. Prognostic significance of monoclonal gammopathy in diffuse large B-cell lymphoma. Hematol Oncol. 2019;37(5):634-7.
Asatiani E, Cohen P, Ozdemirli M, Kessler CM, Mavromatis B, Cheson BD. Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol. 2004;77(2):144-6.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.
Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37:144-52.
Gray RJ. A class of $K$-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-54.
Wöhrer S, Streubel B, Bartsch R, Chott A, Raderer M. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res. 2004;10:7179-81.
Maiolo E, Alma E, Napodano C, Gulli F, Bellesi S, Cuccaro A. The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). Leuk Lymphoma. 2020;61(5):1133-9.
Huet S, Sujobert P, Salles G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat Rev Cancer. 2018;18(4):224-39.